Eli Lilly is a global biopharma company whose exceptionally profitable cardiometabolic franchises, led by Mounjaro and Zepbound, are driving a high-quality growth phase: revenue rose 55.5% year over year and earnings rose 168.0% year over year in the most recent quarter, while gross, operating, and net margins were 83.5%, 45.9%, and 35.0%, respectively.
LLY
· Healthcare · Drug Manufacturers - General
· Market cap $1110.4B
QuantHub Original Research · Updated 2026-07-17
·
High QualityA-tier business, fair-tier valuation with 31.7% upside to $1,552.32 fair value and identifiable 2026 earnings and pipeline catalysts.CheapIn Buy Zone
LLY is 30% below fair value and in its buy zone. Consider adding to your position.
QuantHub Research: Investment Thesis
Investing (Rev Growth >20%) Phase
Eli Lilly is a global biopharma company whose exceptionally profitable cardiometabolic franchises, led by Mounjaro and Zepbound, are driving a high-quality growth phase: revenue rose 55.5% year over year and earnings rose 168.0% year over year in the most recent quarter, while gross, operating, and net margins were 83.5%, 45.9%, and 35.0%, respectively. Business quality is high because tirzepatide leadership, manufacturing scale, payer infrastructure, brand, and a deep follow-on pipeline create meaningful competitive advantages, although product concentration and pricing pressure remain material. At $1,179.09, the shares trade at 41.73x trailing earnings, 34.32x EV/EBITDA, and 77.67x free cash flow, reflecting elevated expectations, but the valuation is classified as fair relative to its five-year history and the $1,552.32 fair-value estimate indicates 31.7% upside, supported by raised 2026 guidance, Foundayo adoption, and later-2026 retatrutide data.
LLY is not conventionally cheap on absolute multiples, trading at 41.73x trailing P/E, 34.32x EV/EBITDA, 14.6x sales, and 77.67x free cash flow. However, the market is pricing an unusually durable period of high growth rather than a mature pharmaceutical earnings stream: 2026 non-GAAP EPS guidance of $35.50 to $37.00 implies roughly 32.5x the $36.25 midpoint at the current share price, while Q1 revenue increased 56% and non-GAAP EPS increased 156%. The shares are assessed as fair versus Lilly's five-year valuation history and screen 31.7% below the $1,552.32 fair-value estimate. Sell-side sentiment remains Strong Buy, with a $1,338.70 average target implying 13.5% upside, although vendor targets vary materially; recent bullish actions included Citi raising its target to $1,600, Bernstein raising its target to $1,385, and UBS raising its target to $1,425. The valuation discount to fair value is justified only if tirzepatide volume growth, international expansion, supply execution, and follow-on obesity products sustain earnings growth despite falling realized prices and increasing competition.
12–18 Month Outlook
By early 2028, Lilly is likely to remain predominantly defined by the scale and durability of its cardiometabolic portfolio, but investors will be judging whether it has converted exceptional incretin demand into a broader, more durable platform. The base case is for revenue to remain well above the $82 billion to $85 billion 2026 guidance range as Mounjaro, Zepbound, international access, Medicare Bridge uptake, and manufacturing additions support continued volume growth. The key swing factors will be Foundayo's ability to improve against oral Wegovy, retatrutide's later-2026 pivotal readouts, realized-price trends after the 13% Q1 decline, and whether Lilly can preserve leadership share against Novo Nordisk. Even with operational execution, the stock could underperform if growth normalizes faster than expected because current valuation multiples already embed sustained high earnings growth.
Bull vs Bear
Bull Case
Mounjaro generated $8.662 billion of Q1 2026 revenue, up 125% year over year, while Zepbound generated $4.160 billion, up 80%, demonstrating that Lilly's two core incretin franchises remain powerful volume-growth engines.
Lilly held a 60.1% U.S. incretin prescription share and a 53.2% international incretin revenue share in Q1 2026, ahead of Novo Nordisk's 39.4% and 46.8%, respectively.
Management raised 2026 guidance after Q1 to $82 billion to $85 billion of revenue and $35.50 to $37.00 of non-GAAP EPS, signaling confidence in continued demand, capacity expansion, and operating leverage.
Retatrutide produced 28.3% average weight loss at 80 weeks in the TRIUMPH-1 trial, creating a potentially differentiated next-generation obesity franchise if subsequent pivotal data remain favorable.
The $1,552.32 fair-value estimate implies 31.7% upside from $1,179.09, while the August 5, 2026 earnings release can validate continued demand, supply availability, and Foundayo uptake.
Bear Case
Mounjaro and Zepbound account for a substantial share of company growth, making Lilly vulnerable to safety issues, reimbursement restrictions, competitive losses, or slower demand in the incretin category.
Company-wide realized prices declined 13% in Q1 2026, showing that volume growth is already being partially offset by rebates, payer negotiations, and access-related pricing pressure.
Foundayo's early launch trajectory lagged Novo Nordisk's oral Wegovy, with 24,303 weekly prescriptions for Foundayo versus 147,500 for oral Wegovy as of July 17, 2026.
The shares carry elevated absolute valuation multiples of 41.73x trailing P/E, 34.32x EV/EBITDA, and 77.67x free cash flow, leaving limited tolerance for a growth deceleration or margin disappointment.
Lilly incurred $279 million of Q1 2026 special charges related to litigation, and ongoing legal, regulatory, product-liability, and intellectual-property matters could pressure cash flow and investor sentiment.
Leadership & Competitive Position
David A. Ricks
Tenure9.5 yrs
Insider ownership0.14%
Beats guidance75% of qtrs
Capital allocationExcellent
David A. Ricks has served as chief executive officer since January 2017 and chair since June 2017. His tenure has included the buildout of Lilly's incretin leadership, substantial investment in research and manufacturing capacity, and continued shareholder distributions. Insider ownership is modest as a percentage of shares outstanding but meaningful in dollar terms, with directors and current executive officers collectively owning approximately 1.36 million shares.
Lilly reported 60.1% U.S. incretin prescription share in Q1 2026 and 53.2% international incretin revenue share, compared with Novo Nordisk at 39.4% and 46.8%, respectively. Its injectable incretin position is strengthening, though Foundayo's early oral-obesity prescription ramp has lagged oral Wegovy.
Competitors: Novo Nordisk (NVO), Amgen (AMGN), Pfizer (PFE)
Disruption: Medium because Novo Nordisk and other obesity-drug entrants can compete on efficacy, convenience, supply, and payer economics, while oral therapies may reduce differentiation for injectable products.
QuantHub Research
Valuation
Multiple
Current
Median 3yr
Median 5yr
Min 5yr
Max 5yr
P/E
41.73x
90.37x
71.01x
41.73x
307.79x
P/S
14.6x
18.84x
16.59x
10.86x
27.45x
P/FCF
77.67x
87.01x
50.18x
21.82x
404.13x
P/S 14.60x vs 5yr range 10.86-27.45x (P25=13.66x, median=16.59x, P75=19.69x)
Price Outlook (5-Year)
Bear
$1242
0.8%/yr
Base
$1552
5.4%/yr
fair value
Bull
$1863
9.3%/yr
Bear/Base/Bull anchored to QuantHub fair value estimate. Base = headline fair value; Bear −20%; Bull +20%.
Results will provide the first major update after Q1 on Mounjaro and Zepbound demand, realized pricing, manufacturing supply, updated guidance, and Foundayo sales trends.
high
2026-H2
Retatrutide TRIUMPH trial readouts
Additional TRIUMPH-2 diabetes and TRIUMPH-3 cardiovascular-disease data are expected later in 2026 and could reinforce retatrutide's position as a potential next-generation obesity and cardiometabolic franchise.
high
2026-H2
Medicare Bridge access uptake
Medicare GLP-1 Bridge access began on July 1, 2026, and subsequent prescription and coverage trends can demonstrate whether access expansion accelerates obesity-drug adoption.
medium
Risks
Product Concentration Risk
high
Mounjaro and Zepbound produced $8.662 billion and $4.160 billion, respectively, in Q1 2026, making Lilly heavily dependent on a small number of incretin products for revenue growth and earnings.
Pricing and Regulatory Pressure
high
Company-wide realized prices fell 13% in Q1 2026, and government access expansion, payer rebates, global price controls, and Inflation Reduction Act exposure could further reduce pricing power and margins.
Manufacturing and Supply Constraints
medium
Demand for incretin medicines remains unusually high, so manufacturing capacity, supply-chain execution, and product availability are critical to converting demand into revenue and maintaining market share.
Litigation and Special Charges
medium
Lilly recorded $279 million of Q1 2026 special charges related to litigation, while ongoing product-liability, intellectual-property, counterfeit, and illegally compounded-product matters could create further costs or disruption.
Competitive Intensity
high
Novo Nordisk remains the principal incretin competitor, and Foundayo recorded 24,303 weekly prescriptions versus 147,500 for Novo's oral Wegovy, highlighting competitive risk in the oral-obesity market.
Clinical, Safety and Acquisition Execution
medium
Foundayo's label includes warnings involving pancreatitis, severe gastrointestinal reactions, acute kidney injury, hypoglycemia, gallbladder disease, and other risks, while retatrutide remains investigational and the AtaiBeckley acquisition adds integration and development risk.
Growth Engines
Mounjaro diabetes expansionscaling
Mounjaro generated $8.662 billion in Q1 2026 revenue, up 125% year over year, supported by broad type 2 diabetes demand and ongoing international expansion.
Zepbound obesity penetrationscaling
Zepbound generated $4.160 billion in Q1 2026 revenue, up 80% year over year, addressing a large obesity and overweight population with potential expansion into cardiometabolic comorbidities.
Foundayo oral obesity accessearly
Foundayo broadens Lilly's obesity opportunity to patients who prefer a daily oral treatment and benefits from expanded U.S. retail availability and Medicare GLP-1 Bridge access beginning July 1, 2026.
Retatrutide next-generation obesityearly
Retatrutide could expand the addressable obesity market through differentiated efficacy, with 28.3% average weight loss reported at 80 weeks in TRIUMPH-1, subject to further clinical and regulatory success.
Immunology and neuroscience pipelineearly
Products including Ebglyss, Omvoh, Jaypirca, and Kisunla provide diversification beyond incretins, while the proposed AtaiBeckley acquisition adds treatment-resistant-depression programs.
FDA approved Foundayo for chronic weight management
The approval established Lilly's oral obesity offering, broadening access beyond injectable therapies but introducing a direct competitive comparison with Novo Nordisk's oral Wegovy.
2026-04-30
Lilly reported strong first-quarter 2026 results and raised guidance
Revenue reached $19.799 billion, up 56% year over year, and management raised 2026 revenue guidance to $82 billion to $85 billion and non-GAAP EPS guidance to $35.50 to $37.00.
2026-05-21
Retatrutide produced substantial weight-loss results in TRIUMPH-1
The 28.3% average weight-loss result at 80 weeks supports a potentially differentiated future obesity franchise, although additional pivotal data are still pending.
2026-07-01
Medicare GLP-1 Bridge access began
Expanded access can improve affordability and increase eligible demand for Lilly's cardiometabolic products, with the pace of uptake remaining an important variable.
2026-07-16
Lilly agreed to acquire AtaiBeckley
The transaction includes approximately $2.8 billion upfront plus up to $1.0 billion in contingent milestones and expands Lilly's treatment-resistant-depression pipeline, while adding clinical, regulatory, capital-allocation, and integration risks.
This is AI-powered fundamental analysis built from scratch — not aggregated analyst ratings. Get this research for your entire portfolio plus daily briefings, research signals, and options income.
QuantHub research is focused on quality businesses with durable competitive advantages — companies we'd want to own for 3–5 years or more. We are not short-term traders. Every analysis is built around a single question: is this a great business available at a reasonable price for a long-term investor?
We start where most analysts finish: the fundamentals. For every company, our AI ingests years of financial statements — revenue, margins, free cash flow, and how the business has been valued by the market across multiple cycles. But numbers alone don't tell you whether a business is worth owning.
The harder work is qualitative. We assess the competitive moat: is it widening or eroding? We read the leadership track record — how capital has been allocated, whether management has earned trust through consistent execution. We look at what the market is afraid of, and whether that fear is priced in fairly or irrationally.
Valuation is always relative. A stock is cheap or expensive compared to its own history. We build scenario matrices anchored to 5-year historical multiples, then ask: what has to go right for the upside case, and what's the floor if it doesn't?
Finally, we write an 18-month forward outlook — not a price target, but a mental model of where this business will be and what the narrative will look like. Every note is dated and versioned. When material facts change, we update the thesis.
Frequently Asked Questions
Is LLY undervalued?
Yes, LLY appears undervalued at the current price of $1,196.04, trading below our fair value estimate of $1,552.32 (+30% upside). QuantHub considers this a buy zone.
What is LLY's fair value?
QuantHub Research estimates LLY's fair value at $1,552.32 based on our proprietary valuation model incorporating historical P/S, P/E, and P/FCF multiples over a 5-year range.
What are the key risks for LLY?
Product Concentration Risk: Mounjaro and Zepbound produced $8.662 billion and $4.160 billion, respectively, in Q1 2026, making Lilly heavily dependent on a small number of incretin products for revenue growth and earnings. Pricing and Regulatory Pressure: Company-wide realized prices fell 13% in Q1 2026, and government access expansion, payer rebates, global price controls, and Inflation Reduction Act exposure could further reduce pricing power and margins. Manufacturing and Supply Constraints: Demand for incretin medicines remains unusually high, so manufacturing capacity, supply-chain execution, and product availability are critical to converting demand into revenue and maintaining market share.
What is the bull case for LLY?
Mounjaro generated $8.662 billion of Q1 2026 revenue, up 125% year over year, while Zepbound generated $4.160 billion, up 80%, demonstrating that Lilly's two core incretin franchises remain powerful volume-growth engines. Lilly held a 60.1% U.S. incretin prescription share and a 53.2% international incretin revenue share in Q1 2026, ahead of Novo Nordisk's 39.4% and 46.8%, respectively. Management raised 2026 guidance after Q1 to $82 billion to $85 billion of revenue and $35.50 to $37.00 of non-
How confident is QuantHub in LLY?
QuantHub has high conviction in LLY. Research last updated 2026-07-17.